High impact
Speech Therapy (CPB 0243, reviewed 2026-05-13)
Aetna·Effective May 13, 2026
Aetna updated its Speech Therapy policy (CPB 0243, effective May 13, 2026) clarifying medical necessity criteria, non-covered services, and experimental treatments. Key changes include explicit exclusion of altered auditory feedback devices for stuttering, facilitated communication, Orton Gillingham approach, post-COVID-19 extubation dysphonia treatment, and transcutaneous electrical nerve stimulation (TENS) for speech/swallowing. The policy reinforces the 60-day treatment limit for HMO plans per condition and requires detailed written treatment plans with physician approval.